AAV2.7m8 vector system (inner ear&retina-validated AAV expression and packaging plasmids) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi (GM) AAV2 variant (AAV2.7m8) Vector system is including: 1) AAV2 variant (AAV2.7m8) Rep-Cap plasmid (AAV2 variant (AAV2.7m8)-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).

You can produce AAV2 variant (AAV2.7m8) particle in 293T cell line in high titer using GeneMedi's AAV2 variant (AAV2.7m8) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV2.7m8 vector has been validated in inner ear and the retina tissue. AAV2.7m8 infects both inner hair cells (IHCs) and outer hair cells (OHCs) with high efficiency. In addition, AAV2.7m8 infects inner pillar cells and inner phalangeal cells with high efficiency, with potential applications in tissue-specific gene therapy.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.

Target products collectionGo to AAV vector system >>

pdfMap Download

Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-PK06 AAV2 variant (AAV2.7m8) Vector System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 3024
P-PK06 AAV2 variant (AAV2.7m8) Vector System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Biotech & Pharma & Medical Device & Diagnostics
P-PK06 AAV2 variant (AAV2.7m8) Vector System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK06 AAV2 variant (AAV2.7m8) Vector System (Amp resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid, ≥10mg
2. AAV Helper Plasmid, ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg
 All
P-PK06-Kan AAV2 variant (AAV2.7m8) Vector System (Kan resistance)
1. AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Kan resistance) , ≥10mg
2. AAV Helper Plasmid (Kan resistance) , ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg
 All
P-RC06 AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Academic 1719
P-RC06 AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		Biotech & Pharma & Medical Device & Diagnostics
P-RC06 AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance)
Size：5ug 		CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC06 AAV2 variant (AAV2.7m8) Rep-Cap Plasmid (Amp resistance)
Size：≥10mg 		All
P-RC06-Kan AAV2 variant (AAV2.7m8) Rep-Cap Plasmid(Kan resistance)
Size：≥10mg 		All
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System.
GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production& amplification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
METTL3-mediated N6-methyladenosine mRNA modification enhances long-term memory consolidation Cell Research 2018/10/8
Neuraminidase 1 is a driver of experimental cardiac hypertrophy European Heart Journal 2021/6/28
LPA2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction Circulation Research 2022/8/19
TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer Science Translational Medicine 2022/1/5
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN Journal of Hematology&Oncology 2021/3/19
B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathway Cell Death & Differentiation 2022/6/16
N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis Nature Communications 2022/3/18
Targeting STING-mediated pro-inflammatory and pro-fibrotic effects of alveolar macrophages and fibroblasts blunts silicosis caused by silica particles Journal of Hazardous Materials 2023/6/22
Hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic SNARE proteins contributing to septic liver injury Autophagy 2023/4/4
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 and FoxO1 Journal of Experimental & Clinical Cancer Research 2023/5/2


Validation data

No data found


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail